Stock LAB LABIANA HEALTH, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Labiana Health, S.A.

Equities

LAB

ES0105638003

Delayed BME
Other stock markets
 05:05:46 2024-06-28 am EDT 		5-day change 1st Jan Change
2.7 EUR 0.00% Intraday chart for Labiana Health, S.A. +6.30% +116.00%
Apr. 26 Labiana Health, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2022 Labiana Health, S.A. acquired 10.31% stake in Trichome Pharma. CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • With regards to fundamentals, the enterprise value to sales ratio is at 0.82 for the current period. Therefore, the company is undervalued.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.

Weaknesses

  • The company is in debt and has limited leeway for investment
  • With an expected P/E ratio at 135 and 13.85 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
LABIANA HEALTH, S.A. Stock Labiana Health, S.A.
+116.00% 20.41M -
ZOETIS INC. Stock Zoetis Inc.
-10.89% 80.52B
B+
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
+0.97% 7.05B
B-
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+20.62% 3.56B
B-
VIRBAC Stock Virbac
-9.32% 3B
B-
VIMIAN GROUP AB Stock Vimian Group AB
+16.72% 1.71B -
VETOQUINOL SA Stock Vetoquinol SA
-7.62% 1.21B -
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-32.96% 1.11B
B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-36.59% 1.06B
C-
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-27.53% 944M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. LAB Stock
  4. Ratings Labiana Health, S.A.